Is Polymyxin B still used today?

Yes, extensively. Polymyxin B is a last-line antibiotic for multidrug-resistant gram-negative infections in hospitals worldwide. It's on the WHO Essential Medicines List and remains FDA-approved. Modern practice uses optimized dosing to minimize toxicity while maintaining efficacy against resistant pathogens.

Can Polymyxin B be used for all bacterial infections?

No. Polymyxin B works only against gram-negative bacteria and some gram-positive organisms. It won't treat gram-positive infections like MRSA (methicillin-resistant Staphylococcus aureus). Its spectrum is limited to its mechanism—bacterial membrane disruption in organisms with accessible lipopolysaccharides.

What's the main safety concern with Polymyxin B?

Kidney damage (nephrotoxicity) is the primary concern, occurring in 20-60% of patients depending on dosing. Nerve damage (neurotoxicity) is also possible. Modern lower-dose regimens have reduced these risks significantly compared to older dosing approaches. Close monitoring of kidney function and neurological status is essential.

Why wasn't Polymyxin B approved in the EU?

The EMA has not granted central authorization for Polymyxin B, reflecting historical availability differences and regulatory philosophy. However, individual European countries may permit its use through national approval pathways, and access is possible in clinical settings where alternatives are exhausted.

How does Polymyxin B compare to colistin?

Both are cyclic peptide antibiotics with similar mechanisms and spectra. Colistin (polymyxin E) is used similarly as a last-line agent. They have comparable efficacy and toxicity profiles, though clinical availability and regulatory status vary by region. Choice often depends on institutional formulary and patient-specific factors.

Polymyxin B: FDA-Approved Antibiotic Peptide Guide

Polymyxin B is an FDA-approved cyclic peptide antibiotic that has been a critical tool in fighting resistant gram-negative bacterial infections for over 70 years. Unlike many compounds in the peptide space, Polymyxin B carries a full regulatory approval in the United States and Canada, making it one of the most clinically validated peptides available. It works by disrupting bacterial cell membranes rather than inhibiting protein synthesis, which is why it remains effective against organisms that have developed resistance to modern antibiotics. With 66 clinical trials documented in the scientific literature, Polymyxin B represents both a historical cornerstone of peptide medicine and an ongoing area of active research into optimizing its use for the most severe infections.

What Is Polymyxin B?

Polymyxin B is a naturally occurring cyclic peptide antibiotic produced by the bacterium Bacillus polymyxa. It belongs to a family of antimicrobial peptides that have been used clinically since the 1950s. The molecule is composed of 11 amino acids arranged in a cyclic structure, which gives it its distinctive mechanism of action and stability.

As an FDA-approved agent, Polymyxin B occupies a unique position in modern medicine. It was developed in an era before the widespread adoption of screening technologies that characterize modern drug development, yet it has survived decades of clinical use and remains on the FDA Essential Medicines List due to its irreplaceable role in treating multidrug-resistant infections.

The Mechanism: How Polymyxin B Kills Bacteria

Polymyxin B's mechanism of action differs fundamentally from most modern antibiotics. Rather than targeting bacterial ribosomes or cell wall synthesis, Polymyxin B disrupts the outer membrane of gram-negative bacteria through a process called lipopolysaccharide (LPS) binding.

Here's how it works:

Membrane Disruption: The cyclic peptide structure contains both hydrophobic and hydrophilic regions. When Polymyxin B encounters the outer membrane of a gram-negative bacterium, it inserts itself into the lipid bilayer. The hydrophobic portions anchor into the fatty acid chains of lipopolysaccharides, while the hydrophilic regions interact with water-soluble components.

Cell Lysis: This insertion destabilizes the membrane integrity, creating pores and leading to leakage of essential cellular contents. Unlike resistance mechanisms that develop against protein synthesis inhibitors, bacteria cannot easily evolve away from membrane disruption—the structural requirement is too fundamental.

Spectrum Limitation: This mechanism explains why Polymyxin B is effective only against gram-negative bacteria and some gram-positive organisms; gram-positive bacteria lack the outer membrane that is the drug's primary target.

This mechanism is why Polymyxin B has remained relevant even as resistance to aminoglycosides, fluoroquinolones, and carbapenems has become widespread. Research indicates that resistance to Polymyxin B develops far more slowly than to other antibiotic classes, making it a critical last-line agent for severe infections caused by extensively drug-resistant organisms.

Clinical Applications and Evidence Base

Polymyxin B is approved for systemic and topical use, though clinical practice has evolved significantly since its introduction. Modern use focuses on severe infections where other options have failed.

Primary Clinical Indications:

Multidrug-Resistant Pseudomonas aeruginosa: Particularly in hospital settings and chronic respiratory infections
Acinetobacter baumannii: A highly resistant gram-negative pathogen responsible for nosocomial infections
Enterobacteriaceae with Carbapenem Resistance: When extended-spectrum beta-lactamase (ESBL) or carbapenem-resistant organisms cause infection
Topical Infections: Combined formulations for wound and skin infections
Ocular Infections: Available in ophthalmic preparations

With 66 documented clinical trials in the scientific literature, research has focused on optimizing dosing regimens, understanding pharmacokinetics in critically ill patients, and exploring combination therapy approaches.

Pharmacokinetics: How Your Body Handles Polymyxin B

Understanding how Polymyxin B moves through the body is crucial to its safe and effective use.

Absorption: When given intravenously (the primary clinical route for systemic infection), Polymyxin B has rapid distribution to tissues. Studies show that the drug penetrates multiple organ systems, though central nervous system penetration is limited—an important consideration for meningitis where dosing strategies differ.

Distribution: The cyclic peptide structure means Polymyxin B doesn't distribute uniformly. It concentrates in tissues with high lipid content, particularly the lungs and kidneys, which has implications both for therapeutic benefit (respiratory infections) and toxicity (renal complications).

Metabolism: Unlike small-molecule drugs, Polymyxin B undergoes minimal hepatic metabolism. This is both an advantage (fewer drug-drug interactions) and a consideration (accumulation in renal impairment).

Elimination: The drug is renally cleared, with most elimination occurring unchanged. In patients with renal dysfunction, dose adjustments are essential to prevent toxicity.

Regulatory Status Across Regions

Polymyxin B's regulatory landscape reflects its long history and evolving clinical role.

United States: FDA-approved for both parenteral (intravenous/intramuscular) and topical use. Available as a mono-agent and in combination formulations. The FDA has maintained approval despite pressure to remove older drugs, recognizing Polymyxin B's irreplaceable role in combating resistance.

Canada: Health Canada has approved Polymyxin B for systemic and topical administration, with similar clinical indications to the US.

European Union: Notably, the EMA has not authorized Polymyxin B as a centrally approved medicine, though individual member states may permit use through national authorization pathways. This reflects different historical availability and regulatory philosophy in Europe.

Compounding: Due to manufacturing discontinuations of injectable formulations in some regions, 503B outsourcing facilities have become important sources of Polymyxin B for hospitals. This has prompted renewed FDA scrutiny and standardization of compounding practices.

Safety Profile and Adverse Effects

Polymyxin B is not a benign drug, and its safety profile must be understood clearly, particularly given its use in vulnerable patient populations.

Nephrotoxicity: The most significant concern. Renal injury occurs in 20-60% of patients receiving Polymyxin B, depending on dosing regimen and patient factors. Modern dosing strategies using lower doses given at longer intervals ("colistin-dosing") have reduced this risk compared to historical regimens.

Neurotoxicity: Ranging from mild paresthesias to severe neuromuscular blockade. This manifests as:

Peripheral neuropathy (tingling, numbness)
Dizziness and vertigo
In severe cases, respiratory muscle weakness

Neurotoxicity is generally reversible upon drug discontinuation but requires careful monitoring.

Drug Interactions: While hepatic metabolism is minimal, Polymyxin B can potentiate neuromuscular blocking agents—a critical consideration in perioperative settings and ICU patients on mechanical ventilation.

Injection Site Reactions: Pain and tissue damage can occur with intramuscular administration, which is why intravenous infusion is preferred.

Monitoring Requirements: Patients on Polymyxin B require:

Baseline and serial renal function tests (creatinine, BUN)
Neurological assessment at baseline and regularly during therapy
Electrolyte monitoring
Careful hydration status management

Research Trends: 66 Clinical Trials and Beyond

The substantial number of clinical trials involving Polymyxin B reflects ongoing efforts to optimize its use in the era of resistance.

Combination Therapy: Research has explored Polymyxin B paired with beta-lactams, fluoroquinolones, and other agents to achieve synergistic bacterial killing and reduce the emergence of resistance during therapy.

Dosing Optimization: Multiple trials have compared traditional dosing (larger, less frequent doses) with modern approaches using lower, more frequent doses to minimize toxicity while maintaining efficacy.

Penetration Studies: Given the limitations in central nervous system penetration, research has investigated whether higher doses or alternative routes (intrathecal administration) improve outcomes in meningitis caused by resistant organisms.

Pediatric Use: Establishing safe and effective dosing in children has been an active area, as renal and neurological development affects drug handling differently than in adults.

Comparator Studies: Trials comparing Polymyxin B directly with colistin (a related cyclic peptide) and with other last-line agents have helped clarify when each is most appropriate.

How Polymyxin B Fits in Modern Antibiotic Stewardship

Polymyxin B represents a paradox in contemporary medicine: it's simultaneously old (approved in the 1950s) and essential (irreplaceable for resistant infections in 2024).

In modern antibiotic stewardship programs, Polymyxin B occupies the final tier of the treatment ladder. It's reserved for confirmed multidrug-resistant gram-negative infections where options like carbapenems, fluoroquinolones, and aminoglycosides have either failed or are contraindicated. This approach preserves Polymyxin B's efficacy and reduces overall toxicity exposure by limiting its use to truly necessary situations.

The emergence of mcr-1 and related resistance genes (which confer Polymyxin resistance to previously susceptible organisms) has added urgency to understanding combination strategies and monitoring for resistance development.

Comparing Polymyxin B to Related Compounds

For those interested in cyclic peptide antimicrobials, understanding the landscape is helpful. Bacitracin is another cyclic peptide antibiotic with a similar historical arc and limited modern use due to toxicity concerns. Unlike Polymyxin B, Bacitracin's primary use is topical. Both represent an important class of therapeutics—naturally derived cyclic peptides—whose mechanisms remain relevant despite the age of their discovery.

The Future of Polymyxin B Research

While Polymyxin B is unlikely to be the focus of large new drug development programs, it remains an active research area in several domains:

Heteroresistance: Understanding how subpopulations within bacterial cultures develop resistance during therapy
Formulation Improvements: Enhanced injectable formulations to reduce local toxicity
Biofilm Penetration: Exploring whether Polymyxin B can effectively treat infections in biofilm matrices (chronic respiratory infections, diabetic ulcers)
Drug Combination Synergy: Identifying the most effective combinations with contemporary agents

Key Takeaways

Polymyxin B stands as a remarkable example of a compound that should be obsolete by modern standards yet remains clinically indispensable. Its cyclic peptide structure, membrane-disruption mechanism, and resistance profile make it irreplaceable for multidrug-resistant gram-negative infections. While its safety profile demands careful monitoring and appropriate patient selection, the alternative—untreatable infections—makes Polymyxin B a cornerstone of last-line antimicrobial therapy.

For healthcare providers, patients, and those interested in peptide science, Polymyxin B illustrates that age doesn't determine relevance; mechanism and efficacy do.

Polymyxin B: The Cyclic Peptide Antibiotic Fighting Resistant Gram-Negative Infections